Early increase in eosinophil count may predict long‐term hypereosinophilia during dupilumab treatment: a 2‐year observational study
Andrea Rampi, Umberto Tanzini, Alessandro Vinciguerra, Giulia Danè, Luca Moroni, Mona‐Rita Yacoub, Matteo Trimarchi
Abstract
KEY POINTS: In a limited subset of patients, dupilumab-induced hypereosinophilia is persistent. Two-month follow-up eosinophil count may predict long-lasting hypereosinophilia.
Topics & Concepts
HypereosinophiliaMedicineDupilumabEosinophilObservational studyEosinophiliaTerm (time)DermatologyInternal medicineImmunologyAtopic dermatitisAsthmaQuantum mechanicsPhysicsEosinophilic Disorders and SyndromesInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisAsthma and respiratory diseases